Hospira Inc. / Abbott Hospital Products Division

Generic Sterile Injectable Pharmaceuticals & Hospital Infusion Therapy

$2.5B Hospira annual sales at spinoff (2004 estimate)

Disease Overview

This deal carved Abbott's Hospital Products Division into a pure-play sterile injectables and infusion-systems company. The category supplies generic acute-care injectables (anesthesia, analgesia, antibiotics, oncology), large-volume IV solutions, and integrated medication-delivery hardware (pumps, sets) used across virtually every US hospital. Margins are thin and capacity-constrained, with chronic shortage risk.

Competitive Landscape

At spinoff, Hospira entered as the largest pure-play US generic injectables manufacturer, competing primarily with Baxter International (large-volume IV and infusion pumps), Bristol-Myers Squibb's Mayne Pharma operations (sold to Hospira itself in 2007), Sandoz/Novartis injectables, Teva Parenteral Medicines, and Bedford Laboratories (Boehringer Ingelheim). The strategic rationale was that Abbott wanted to redeploy capital into higher-margin branded pharmaceuticals (Humira, Tricor) while a stand-alone Hospira could compete on cost and scale in commoditized hospital channels. The Crain's coverage noted Hospira would 'take on $700 million of Abbott's debt' and acquire international hospital-products operating assets for $300 million between 2004-2006. Christopher Begley led the new entity from spinoff per the company's first 10-Q filing. Hospira grew from ~$2.5B to ~$4.5B in revenue by 2014 through Mayne Pharma (2007), Orchid (2009), and Javelin (2010) acquisitions. Pfizer ultimately acquired Hospira for ~$17 billion in September 2015, validating the spinoff thesis. See https://www.sec.gov/Archives/edgar/data/1274057/000110465904015693/a04-6330_110q.htm.